Source: Priyanka Sharma, Mint (Livemint) #Pharma #GLP1 #Semaglutide #Pharmacovigilance #IndiaPharma #DrugSafety #Healthcare #Diabetes #Obesity #PharmaStrategy As GLP-1 use expands, diligent monitoring for adverse effects is crucial, particularly in diverse populations
Unfortunately, Medicare and Medicaid tend not to cover weight loss drugs, especially if theyre only prescribed for weight loss
Optimize your diet to get the best results with semaglutide
Maximum icodec concentration at steady state ( C max,SS,Icodec ) was compared between IcoSema and icodec alone, while the dose-normalized C max,SS,Semaglutide was compared between IcoSema and semaglutide alone, using the same statistical analysis as described above for AUC 0 t ,SD and C max,SD
However, long-term outcomes, cardiovascular effects, and rare safety risks remain under investigation
Each outcome operates on a different timeline, and each delivery method changes when those outcomes become apparent